



AMERICAN BOARD OF DERMATOLOGY

Ταξίς } α & Α' Α' } ΑΤ UÔÁ

MOC PROVIDER SELF STUDY REPORT

øUÜÁÜUXøÜÜÁÜòSøÁUÁÜP VøWòÁøøÜøÖÁ
T UÔÁÜòSøÜÜòÜT òP VÁÜVøXøÜÁ

APPLICATION FOR RE-APPROVAL OF SELF-ASSESSMENT (SA) PROGRAM APPENDIX "B"

MOC SELF STUDY CHECKLIST

- Completed Provider Information Sheet
- Transcript of Diplomates participating in approved MOC SA activities
- Summary of Question-Based Peer Performance
- Responses to Self-Study Questions

Send completed application for re-approval to Pamela Zuziak in the American Board of Dermatology office via e-mail: pzuziak1@hfhs.org

Application fee of \$500 (if required) must accompany this document.

MOC PROVIDER SELF STUDY REPORT

SECTION 1: PROVIDER INFORMATION SHEET

Name of MOC Provider (Organization Name):

**Name of sponsoring dermatologist in charge
of MOC Program for MOC Provider:**

Name of person completing application:

Street Address:

City:

State:

Zip Code:

Telephone:

Fax:

E-Mail:

M O C P R O V I D E R S E L F S T U D Y R E P O R T

How many unique MOC SA Activities \ Uj Y you offerYX since your last approval?

FOR EACH ACTIVITY OFFERED SINCE THE LAST APPROVAL

Name of person directing the MOC SA Activity:

Number of questions:

Area of Focus of SA exercise:

General Dermatology
Medical Dermatology
Pediatric Dermatology
Surgical/Procedural Dermatology
Basic Sciences
Subspecialty Specific (ex: Contact Dermatitis)
QÚ à•] ^&ãç ÁJ ^&ãç ÆÇã óá ^[[, Á

Disease Specific:
QÓã ^æ ^ÁJ ^&ãç ÆÇã óá ^[[, Á

Mechanism used to administer the MOC SA Activity:

Web-based
CD-ROM-based
Audience Response System-based
Written-based
Other
QÚc@i ÆÇã óá ^[[, Á

Describe how you provided feedback to the individual learner:

Describe how you communicated and displayed peer group comparison for each participant:

Cost to Subject:

Was this activity also approved for CME Credit?

→ If YES, how many CME Credits were approved?:

NOTE: Self-assessment programs that offer CME credit must adhere to the standards set forth by the ACCME. The ABD further requires that all self-assessment programs designed for MOC credit, even those not offering CME credit, adhere to these same standards. Standards are [available for review on the ACCME website](#).

MOC PROVIDER SELF STUDY REPORT


SECTION 3: SUMMARY OF QUESTION-BASED PEER PERFORMANCE

Instructions: T U O Á Ú ! [ç ã ^ ! • Á ~ • ó & ~ á ^ Á ã @ Á ç] | æ æ } Á ! Á ^ É ç] ! [ç æ á á Á ^ & c [] æ Á ç G D Á Ç [! á Á [& { ^ } ó ! Á ç & / Á [& { ^ } ó Á & É c ó ç & ~ á • Á @ Á ^ Á ^ ! Á ^ ! f ! { æ & Á } Á @ Á Ú Ç Á Ú ~ ^ • ç } • É Á V @ ! ^ Á @ ~ ! á Á ^ Á } ^ Á ~ { { æ ^ Á [& { ^ } ó ! Á æ & ç } ã ~ ^ Á Ú Ç Á & ç ã É Á G Á T U O Á] ! [ç ã ^ ! • Á • ^ á Á } ^ Á Ú Ç Á & ç ã Á ^] ^ æ á ! É Á ^ æ } * Á } ^ Á ^] ! ! ó @ ç & [à á ^ • Á ç] ^ Á ^ ! Á] ^ ! f ! { æ & Á } | æ • Á ç ! ç] ^ Á ^ ! Á ^ ! f ! { æ & Á } Á • á æ | ^ Á ó [ó Á ~ á á É Á Ú] ! ! ó Á æ Á ^ Á ç æ | æ Á ! Á ! ç @ ç Á ! { É Á Ú ç] ! ^ Á Á æ &] ç æ | Á ^] ! ! ó c | ^ Á ç Á ! [ç ã ^ á á Á @ Á] æ Á Á ! , É Á

Example of MOC SELF-ASSESSMENT PEER PERFORMANCE SUMMARY

8.) MD9Talk: Management of patients with metastatic melanoma
 If a patient with metastatic melanoma is discovered to have a therapy-responsive KIT mutation, which therapy is most likely to offer targeted KIT inhibition?

	Responses
Ipilimumab	3 11.11%
Temozolomide	1 3.70%
<i>Imatinib</i>	22 81.48%
Aldeslakin	0 0%
Dacarbazine	1 3.70%
Totals	27 100%



SECTION 4: MOC SELF-ASSESSMENT RE-APPLICATION
SELF STUDY QUESTION

Instructions: Review the questions and answers from your previous MOC Self-Assessment activity. Did your questions identify clinically relevant knowledge gaps? Please list up to 5 of the most relevant knowledge gaps that you think your Self-Assessment activity identified.

Did your questions identify clinically relevant knowledge gaps? Please list up to 5 of the most relevant knowledge gaps that you think your Self-Assessment activity identified.